Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2007 Mar 29;61(1):133–144. doi: 10.1007/s00280-007-0458-z

Fig. 6.

Fig. 6

Plasma/RBC ratios (Kd) of rapamycin control formulation (open square), rapamycin in PEG-b-PCL (dotted rectangle), and rapa-mycin in PEG-b-PCL + α-tocopherol formulation (filled square) at a) 1 min after IV administration. (n = 4, mean ± SEM) and at b) 24 h after IV administration. (n = 4, mean ± SEM). *Denotes statistical significant difference (P < 0.05) between control and formulation. #Denotes statistical significant difference (P < 0.05) between both formulations